Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Accumulated Expenses (2016 - 2025)

Rocket Pharmaceuticals' Accumulated Expenses history spans 10 years, with the latest figure at $12.3 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 2.93% year-over-year to $12.3 million; the TTM value through Dec 2025 reached $12.3 million, up 2.93%, while the annual FY2025 figure was $12.3 million, 2.93% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $12.3 million at Rocket Pharmaceuticals, up from $11.4 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $12.3 million in Q4 2025 and bottomed at $1.1 million in Q4 2023.
  • The 5-year median for Accumulated Expenses is $4.0 million (2021), against an average of $5.2 million.
  • The largest annual shift saw Accumulated Expenses plummeted 76.01% in 2022 before it soared 1009.01% in 2024.
  • A 5-year view of Accumulated Expenses shows it stood at $4.5 million in 2021, then plummeted by 53.78% to $2.1 million in 2022, then tumbled by 48.59% to $1.1 million in 2023, then skyrocketed by 1009.01% to $11.9 million in 2024, then rose by 2.93% to $12.3 million in 2025.
  • Per Business Quant, the three most recent readings for RCKT's Accumulated Expenses are $12.3 million (Q4 2025), $11.4 million (Q3 2025), and $8.0 million (Q2 2025).